5-溴吡啶-3-硼酸

• 产品号: 686816
• CAS号: 452972-09-7
• 分子式: C5H5BBrNO2
• 分子量: 201.8137
• 纯 度: ≥95%

产品别名

• 标题: 5-Bromopyridine-3-boronic acid
• IUPAC标准名: (5-bromopyridin-3-yl)boronic acid
• IUPAC传统名: 5-bromopyridin-3-ylboronic acid
• 别名: (5-Bromo-3-pyridyl)boronic acid; (3-Bromopyridin-5-yl)boronic acid; (5-bromo-3-pyridinyl)boronic acid

产品登记号

• CAS号: 452972-09-7
• MDL号: MFCD02685634

产品性质

• Empirical Formula (Hill Notation): C5H5BBrNO2
• 纯度: ≥95%
• 熔点: 260 (dec.)
• GHS警示词: Warning
• GHS危险声明: H315-H319-H335
• 欧盟危险性物质标志: 刺激性(Irritant) (Xi)
• 个人保护装置: dust mask type N95 (US), Eyeshields, Gloves
• GHS警示性声明: P261-P305 + P351 + P338
• 危险公开号: 36/37/38
• 安全公开号: 26-36
• 保存温度: 2-8°C
• 德国WGK号: 3

产品详细信息

详细说明 (English)

General description
May contain varying amounts of anhydride.
Packaging
1, 5 g in glass bottle
Application
Reactant for preparation of:
• Thienylpyridyl garlands via cross-coupling with heteroaryl halides1
• Arenes via nickel-catalyzed cross-coupling with potassium aryl- and heteroaryl trifluoroborates2
• Meso-substituted ABCD-type porphyrins by functionalization reactions3
• Analogs of (acetylamino)(dimethylpyrazol)(pyridyl)pyrimidines as A2A adenosine receptor antagonists for the treatment of Parkinson′s disease4
• 5-hydroxy-1,3,2-dioxaborolan-4-ones boronate-amine complexes via heterocyclization with α-oxocarboxylic acids followed by subsequent complexation5
• Radioligands with optimized brain kinetics for PET imaging of nAChR6

详细说明 (简体中文)

General description
可能含不定量的酸酐。
包装
1, 5 g in glass bottle
Application
Reactant for preparation of:
• Thienylpyridyl garlands via cross-coupling with heteroaryl halides1
• Arenes via nickel-catalyzed cross-coupling with potassium aryl- and heteroaryl trifluoroborates2
• Meso-substituted ABCD-type porphyrins by functionalization reactions3
• Analogs of (acetylamino)(dimethylpyrazol)(pyridyl)pyrimidines as A2A adenosine receptor antagonists for the treatment of Parkinson′s disease4
• 5-hydroxy-1,3,2-dioxaborolan-4-ones boronate-amine complexes via heterocyclization with α-oxocarboxylic acids followed by subsequent complexation5
• Radioligands with optimized brain kinetics for PET imaging of nAChR6